DELFI's AI platform uses whole-genome sequencing to detect cancer-associated cfDNA fragmentation patterns in the blood.
DELFI Diagnostics has raised $225.0M in total funding. The most recent round was Series B. The last funding was announced in July 2022.
DELFI Diagnostics's investors include Menlo Ventures, Eli Lilly, Samsara BioCapital, Point72, OrbiMed.
DELFI Diagnostics is headquartered in Palo Alto, United States.
DELFI's AI platform uses whole-genome sequencing to detect cancer-associated cfDNA fragmentation patterns in the blood.
DELFI Diagnostics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DELFI Diagnostics — Funding & Investors." VCBacked, July 18, 2022, https://www.vcbacked.co/company/delfi-diagnostics. Accessed August 13, 2026.
VCBacked. (2022). DELFI Diagnostics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/delfi-diagnostics
{{cite web |title=DELFI Diagnostics — Funding & Investors |url=https://www.vcbacked.co/company/delfi-diagnostics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated